These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 26198345)

  • 1. Antiretroviral pre-exposure prophylaxis implementation in the United States: a work in progress.
    Mayer KH; Hosek S; Cohen S; Liu A; Pickett J; Warren M; Krakower D; Grant R
    J Int AIDS Soc; 2015; 18(4 Suppl 3):19980. PubMed ID: 26198345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
    Adams JL; Shelley K; Nicol MR
    Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020.
    Tanner MR; Miele P; Carter W; Valentine SS; Dunville R; Kapogiannis BG; Smith DK
    MMWR Recomm Rep; 2020 Apr; 69(3):1-12. PubMed ID: 32324724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
    Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
    BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women.
    Mugwanya KK; John-Stewart G; Baeten J
    Expert Opin Drug Saf; 2017 Jul; 16(7):867-871. PubMed ID: 28571500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.
    Zablotska IB; Selvey C; Guy R; Price K; Holden J; Schmidt HM; McNulty A; Smith D; Jin F; Amin J; Cooper DA; Grulich AE;
    BMC Public Health; 2018 Feb; 18(1):210. PubMed ID: 29394918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.
    Sullivan PS; Giler RM; Mouhanna F; Pembleton ES; Guest JL; Jones J; Castel AD; Yeung H; Kramer M; McCallister S; Siegler AJ
    Ann Epidemiol; 2018 Dec; 28(12):833-840. PubMed ID: 30037634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review.
    Mayer KH; Agwu A; Malebranche D
    Adv Ther; 2020 May; 37(5):1778-1811. PubMed ID: 32232664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS; Mayer KH
    Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake of HIV Preexposure Prophylaxis Among Commercially Insured Persons-United States, 2010-2014.
    Wu H; Mendoza MC; Huang YA; Hayes T; Smith DK; Hoover KW
    Clin Infect Dis; 2017 Jan; 64(2):144-149. PubMed ID: 27986691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Getting pre-exposure prophylaxis (PrEP) to the people: opportunities, challenges and emerging models of PrEP implementation.
    Sullivan PS; Siegler AJ
    Sex Health; 2018 Nov; 15(6):522-527. PubMed ID: 30476461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
    Özdener AE; Park TE; Kalabalik J; Gupta R
    Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
    Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
    Mugwanya KK; Baeten JM
    Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards a fair consideration of PrEP as part of combination HIV prevention in Latin America.
    Ravasi G; Grinsztejn B; Baruch R; Guanira JV; Luque R; Cáceres CF; Ghidinelli M
    J Int AIDS Soc; 2016; 19(7(Suppl 6)):21113. PubMed ID: 27760687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PrEP implementation research in Africa: what is new?
    Cowan FM; Delany-Moretlwe S; Sanders EJ; Mugo NR; Guedou FA; Alary M; Behanzin L; Mugurungi O; Bekker LG
    J Int AIDS Soc; 2016; 19(7(Suppl 6)):21101. PubMed ID: 27760680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PrEParing for Preexposure Prophylaxis.
    Zappas MP; Foreman RM
    J Dr Nurs Pract; 2020 Mar; 13(1):3-8. PubMed ID: 32701461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.
    Trang TP; Dong BJ; Kojima N; Klausner JD
    Expert Opin Drug Saf; 2016 Sep; 15(9):1287-94. PubMed ID: 27391203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
    JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.